-- 德國股市週一開盤走低,藍籌股DAX指數下跌0.19%,市場正等待本週內主要央行公佈的利率決議。 聯準會將於週三宣布最新貨幣政策決定,而歐洲央行和英國央行的決議將於週四公佈。 在國內,德國消費者信心似乎進一步惡化。受收入下降和經濟預期下滑的影響,GfK 2026年5月消費者信心指數從一個月前修正後的-28.1點降至-33.3點。該指數為2023年2月以來的最低水平,低於Investing.com預測的-30.2點。 「受伊朗戰爭引發的能源價格上漲影響,德國3月份通膨率從1.9%升至2.7%,導致大多數消費者再次預期物價上漲。儘管4月份價格預期指標的漲幅略低於3月份——這可能是由於加油站油價下跌所致——但與年初相比,該指標水平有所上升。」由GfK支持的NIM消費者信心指數調查顯示。 同時,在高度地緣政治不確定性的背景下,德國出口前景略有改善,積極的預期大致抵消了消極的預期。 ifo經濟研究所的出口預期指標從上月的-0.7點上升至4月的0.1點。 在企業新聞方面,根據彭博新聞社援引匿名消息人士報道,德國官員與歐洲各銀行舉行了非正式的初步會談,探討新的戰略投資者收購或接管德國商業銀行(CBK.F)股份的可能性。據稱,持有德國商業銀行12%股份的德國政府正在尋找替代方案,以取代義大利聯合信貸銀行(UniCredit)可能提出的收購要約。聯合信貸銀行於2026年初提交了收購要約。德國商業銀行股價收盤上漲2.39%。
Related Articles
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.